<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062174</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-IUSCCC-0758</org_study_id>
    <nct_id>NCT05062174</nct_id>
  </id_info>
  <brief_title>Targeting Progesterone Signaling for Breast Cancer Prevention in BRCA1 Carriers: a Pilot Study</brief_title>
  <official_title>Targeting Progesterone Signaling for Breast Cancer Prevention in BRCA1 Carriers: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine how a single dose of MIFEPREX® (mifepristone) affects&#xD;
      the breast tissue in patients with BRCA1 (a gene that normally acts to restrain the growth of&#xD;
      cells in the breast, but if it mutates may lead to breast cancer) mutations undergoing a&#xD;
      planned prophylactic mastectomy (having one or both breasts removed).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, prospective, observational trial enrolling up to 10 patients within&#xD;
      Indiana University Simon Comprehensive Cancer Center. Eligible women will be consented to&#xD;
      undergo breast biopsy 2-6 days prior to prophylactic mastectomy and take one dose of&#xD;
      mifepristone 2 days prior to prophylactic mastectomy. If the initial biopsy is obtained on&#xD;
      Day -2, the mifepristone should be taken AFTER the biopsy. Tissue from the ipsilateral breast&#xD;
      will be taken at the time of mastectomy.&#xD;
&#xD;
      Primary Objective To determine the impact of a single 200 mg dose of mifepristone on gene&#xD;
      expression and metabolomic alterations in breast tissue of women with BRCA1 mutations who are&#xD;
      planning prophylactic mastectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of mifepristone</measure>
    <time_frame>From baseline (day -2 to day -6) to Breast surgery (day 0)</time_frame>
    <description>To determine the impact of a single 200 mg dose of mifepristone on gene expression and metabolomic alterations in breast tissue of women with BRCA1 mutations.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>BRCA1 Mutation</condition>
  <condition>High-grade Serous Ovarian Cancer</condition>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>mifepristone + surgery</arm_group_label>
    <description>Mifepristone is taken orally as a one-time only dose between 48 and 56 hours before your planned prophylactic mastectomy surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone 200 MG</intervention_name>
    <description>Orally, one time dosage of 200 mg</description>
    <arm_group_label>mifepristone + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prophylactic mastectomy</intervention_name>
    <description>Planned prophylactic mastectomy (having one or both breasts removed).</description>
    <arm_group_label>mifepristone + surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      random core biopsy of breast tissue from both breasts at time of biopsy and pre-planned&#xD;
      mastectomy, as well as blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        10 BRCA-1 mutation carriers who plan to undergo prophylactic mastectomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 old at the time of informed consent&#xD;
&#xD;
          2. Known pathogenic germline BRCA1 mutation. The mutation must have been discovered by a&#xD;
             CLIA- approved next generation sequencing panel (such as Myriad, Invitae, Ambry, etc)&#xD;
             and confirmed by the PI.&#xD;
&#xD;
          3. Planning to undergo prophylactic risk reducing mastectomy&#xD;
&#xD;
          4. Premenopausal, defined as:&#xD;
&#xD;
               1. At least one ovary remains in situ, AND&#xD;
&#xD;
               2. Estradiol &gt; 20 or last menstrual period within the prior 3 months&#xD;
&#xD;
               3. Prior hysterectomy is allowed as long as at least one ovary remains in place&#xD;
&#xD;
          5. Must not be pregnant or nursing&#xD;
&#xD;
             a. Must have a negative urine pregnancy test for registration and between -6 to day -2&#xD;
             prior to receiving mifepristone&#xD;
&#xD;
          6. Ability to provide written informed consent and HIPAA authorization&#xD;
&#xD;
          7. Agrees to pre-treatment core biopsy with donation to the IUSCCC Komen Normal Tissue&#xD;
             Bank. Patient will sign a separate informed consent for donation to the IUSCCC Komen&#xD;
             Normal Tissue Bank.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients may not have used progesterone-only contraceptives (i.e. Depo- Provera)&#xD;
             within the last 6 months. Combination estrogen/progesterone or estrogen only&#xD;
             contraceptives are allowed.&#xD;
&#xD;
          2. Presence of an intrauterine device&#xD;
&#xD;
          3. Personal history of breast or ovarian cancer&#xD;
&#xD;
          4. Active heavy smoker, defined as 10 or more cigarettes per day on any occasion in the&#xD;
             past 30 days&#xD;
&#xD;
          5. Uncontrolled chronic medical condition, including insulin dependent diabetes, NYHA&#xD;
             class II, III or IV congestive heart failure, unstable angina, history of myocardial&#xD;
             infarction, chronic pulmonary conditions including uncontrolled asthma (symptoms &gt; 2&#xD;
             days/week) or dyspnea requiring oxygen, peripheral vascular disease, symptomatic&#xD;
             anemia, uncontrolled psychiatric conditions, chronic kidney disease, or liver disease&#xD;
             (cirrhosis, NAFLD, etc.)&#xD;
&#xD;
          6. Requiring ongoing therapy with strong CYP3A4 inhibitor, steroids, or&#xD;
             immunosuppressants (i.e. tacrolimus, cyclosporine, etc.). Please see appendix for full&#xD;
             list of excluded co-medications. If questions, please ask the PI.&#xD;
&#xD;
          7. History of life- threatening allergic reaction to local anesthesia (lidocaine,&#xD;
             xylocaine).&#xD;
&#xD;
          8. Contraindications including but not limited to allergic reactions to mifepristone or&#xD;
             other prostaglandins, or inherited porphyrias&#xD;
&#xD;
          9. For the purposes of invasive breast biopsies, women must not be receiving therapeutic&#xD;
             anticoagulation or antiplatelet agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarah Ballinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Sollars, RN</last_name>
    <phone>317-278-5117</phone>
    <email>jlsherma@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tarah Ballinger, MD</last_name>
    <email>tarab@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IU Health Joe and Shelly Schwarz Cancer Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Dutkevitch, RN</last_name>
      <phone>317-278-5618</phone>
      <email>sdutkevi@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Tarah Ballinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin &amp; Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Tarah J Ballinger, MD</investigator_full_name>
    <investigator_title>Assistant Professor Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>progesterone signaling</keyword>
  <keyword>mifepristone</keyword>
  <keyword>glucocorticoid receptor</keyword>
  <keyword>androgen receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

